INmune Bio Data Shows Resistance-Breaking Potential in HER2+ Breast Cancer
Event summary
- INmune Bio presented preclinical data at AACR 2026 demonstrating INB03 (XPro1595) enhances the efficacy of tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer models.
- The data indicates INB03 overcomes resistance to TKIs like lapatinib and tucatinib, significantly reducing cell proliferation and metastatic spread.
- The mechanism involves INB03 down-regulating MUC4, a protein that shields HER2 and prevents therapies from binding effectively.
- The research was conducted in collaboration with the Instituto de Biología y Medicina Experimental (IBYME-CONICET) in Buenos Aires, Argentina.
The big picture
The ongoing challenge of drug resistance in HER2-positive breast cancer represents a significant clinical and commercial hurdle. INmune Bio’s data suggests a novel approach to circumventing this resistance by targeting the TNF pathway, potentially broadening the applicability of existing HER2-targeted therapies. The company's broader platform strategy, encompassing CORDStrom™, XPro™, and INKmune®, introduces complexity but also diversification of risk.
What we're watching
- Clinical Translation
- The preclinical efficacy observed will need to be replicated in human clinical trials to validate INB03’s potential as a combination therapy.
- Regulatory Pathway
- Given the complexity of combination therapies, the regulatory pathway for INB03 will likely be more challenging than for single-agent drugs, potentially impacting timelines.
- Commercial Adoption
- The success of INB03 will depend on its ability to address a significant unmet need in a market already crowded with HER2-targeted therapies, requiring a clear value proposition for physicians and patients.
Related topics